insights_auto
Why is LSR down 8.00%?
Dive Deeperchevron_right
LSR:FRA
CEL-SCI Corp
€1.38
arrow_downward
-8.00%(-0.12) 1D
Oct 20, 8:02:03 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LSR...
Open
€1.38
High
€1.38
Low
€1.38
Mkt. cap
27.79M
Avg. vol.
51.00
Volume
0.00
52-wk high
€8.05
52-wk low
€0.76
No. of employees
43
Open
€1.38
High
€1.38
Low
€1.38
Mkt. cap
27.79M
Avg. vol.
51.00
Volume
0.00
52-wk high
€8.05
52-wk low
€0.76
No. of employees
43
News stories
From web sources and news partners
ChartMill
·
1 hour ago
Most Active S&P 500 Stocks in Today's Session
FXEmpire
·
30 minutes ago
Dow Jones Price Forecast: Bulls Eye 57,000 as October 6 Low Remains Key
Insider Monkey
·
1 hour ago
Ciena (CIEN): Is the AI-Optical Boom Enough to Carry It Into the S&P 500?
Yahoo Finance
·
2 hours ago
United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500?
Profile
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
About CEL-SCI Corp
CEO-
Employees43
FoundedMar 1983
HeadquartersVienna, Virginia, United States
SectorBiotechnology
Websitecel-sci.com